# Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

> **NCT00326339** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** R788
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00326339
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-12
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2009-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326339, "Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00326339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*